Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A | P08908 | 11/20 | 0.44 |
| ▸ | SLC6A4 | P31645 | 11/20 | 0.44 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.43 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.43 |
| ▸ | HTR2A | P28223 | 2/20 | 0.41 |
| ▸ | HTR2C | P28335 | 2/20 | 0.41 |
| ▸ | IDO1 | P14902 | 1/20 | 0.40 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7551792 | 0.88 | ADRA1A (0.48) | HTR1ASLC6A4ADRA1ATAAR1HTR2A | |
| SCHEMBL23704945 | 0.87 | HTR2A (0.43) | HTR1ASLC6A4ADRA1ATAAR1HTR2A | |
| SCHEMBL15289008 | 0.85 | HTR1A (0.43) | HTR1ASLC6A4ADRA1ATAAR1HTR2A | |
| SCHEMBL15376943 | 0.83 | HTR1A (0.45) | HTR1ASLC6A4ADRA1ATAAR1HTR2A | |
| SCHEMBL17330013 | 0.83 | HTR1A (0.45) | HTR1ASLC6A4ADRA1ATAAR1HTR2A | |
| SCHEMBL989673 | 0.81 | TAAR1 (0.66) | HTR1ASLC6A4ADRA1ATAAR1HTR2A | |
| SCHEMBL31627757 | 0.81 | TAAR1 (0.66) | HTR1ASLC6A4ADRA1ATAAR1HTR2A | |
| SCHEMBL29351990 | 0.81 | CYP2D6 (0.51) | HTR1ASLC6A4ADRA1ATAAR1HTR2A | |
| SCHEMBL6401187 | 0.81 | CYP2D6 (0.51) | HTR1ASLC6A4ADRA1ATAAR1HTR2A | |
| SCHEMBL7668586 | 0.81 | HSD17B10 (0.43) | HTR1ASLC6A4ADRA1ATAAR1HTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130150350-A1 | Derivatives of 1-Phenyl-1,5-Dihydro-Benzo[B] [1,4]Diazepine-2,4-Dione as Inhibitors of HIV Replication | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-06-13 | — | — | US | disclosed |
| US-20130150350-A1 | Derivatives of 1-Phenyl-1,5-Dihydro-Benzo[B] [1,4]Diazepine-2,4-Dione as Inhibitors of HIV Replication | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-06-13 | — | — | US | disclosed |
| WO-2011100838-A1 | DERIVATIVES OF 1-PHENYL-1,5-DIHYDRO-BENZO[B] [1.4]DIAZEPINE-2.4-DIONE AS INHIBITORS OF HIV REPLICATION | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-08-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130150350-A1 | Derivatives of 1-Phenyl-1,5-Dihydro-Benzo[B] [1,4]Diazepine-2,4-Dione as Inhibitors of HIV Replication | MED1, ZC3HAV1, BET1 | HTR1A 1056/4885SLC6A4 4056/4885ADRA1A 943/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.